Press Release

Study: WHO Tool Underestimates Need for Osteoporosis Treatment

April 29, 2014

Younger patients suffering first broken bone more likely to be mislabeled low risk

Washington, DC—The World Health Organization’s tool for assessing bone fracture risk underestimates the true dangers for people who are younger than 65 or have been treated for a single broken bone, according to a new study published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism (JCEM).

A WHO task force developed the Fracture Risk Assessment Tool (FRAX) to help predict the likelihood of adults between the ages of 40 and 90 breaking a bone. FRAX is designed to evaluate the chances that a person will break a bone in a minor fall, which is called a fragility fracture. Such fractures can reduce mobility and even increase the risk of death.

The FRAX tool is designed to help physicians identify osteoporosis cases that cannot be readily diagnosed through bone mineral density testing. More than half of fragility fractures occur in people who do not meet the bone mineral density standards to be diagnosed with osteoporosis.

“Although FRAX is a helpful tool and provides important information, it should not be used as the unique and definitive gold standard for determining whether or not to treat a patient for osteoporosis or weakening bones,” said one of the study’s authors, Gilles Boire, MD, MSc, of the University of Sherbrooke in Quebec, Canada. “The test fails to identify some patients who would benefit from treatment to prevent future fractures.”

The prospective cohort study used the Canadian BMI-FRAX form of the tool to gauge fracture risk among 1,399 patients who were identified with a fragility fracture between June 2007 and May 2012. The Canadian version of the tool incorporates national data on fracture rates.

Prior to sustaining the fragility fracture, only 42.7 percent of these patients were considered high risk, according to the Canadian BMI-FRAX tool. Even after sustaining an initial fracture, 24 percent of the patients remained categorized as low risk and nearly 20 percent were considered moderate risk. During a four-year follow-up period, more than a third of the patients who had recurrent fractures were not categorized as high risk under the Canadian BMI-FRAX calculation.

In more than half of the patients treated for an initial fragility fracture, the FRAX score did not reach the Canadian threshold for preventative treatment. The risk calculator was most likely to underestimate the likelihood of future broken bones in younger patients, men and people presenting their first fragility fracture.

“Identifying individual patients at high risk for fractures would allow for more timely and targeted prevention,” Gilles Boire said. “Physicians should always consider whether osteoporosis treatment would benefit a patient presenting a fragility fracture, regardless of their FRAX or bone mineral density scores.”

Other authors of the study include: Sophie Roux, François Cabana, Nathalie Carrier, Pierre-Marc April and Marie-Claude Beaulieu of the University of Sherbrooke, and Michèle Beaulieu of Merck Canada, Inc.

The study, “The World Health Organisation Fracture Risk Assessment Tool (FRAX) Underestimates Incident and Recurrent Fractures in Consecutive Patients with Fragility Fractures,” is scheduled to appear in the July issue of JCEM.

###

Endocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers. The Endocrine Society is the world’s oldest and largest organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions.

The Society has more than 18,000 members, including scientists, physicians, educators, nurses and students in 122 countries. To learn more about the Society and the field of endocrinology, visit our site at www.endocrine.org. Follow us on Twitter at @TheEndoSociety and @EndoMedia.


All Press Releases

Media Contacts

Colleen Williams Manager, Public Relations Phone: (202)-971-3611 cwilliams@endocrine.org

Jenni Glenn Gingery Associate Director, Communications and Media Relations Phone: (202)-971-3655 jgingery@endocrine.org

Back to top
Short on time?

We'll come to you...

Get updates on the latest breakthroughs, clinical practice guidelines, and career development opportunities, straight to your inbox

Then take the next step: Set up your free website account and get exclusive access to even more great tools & content!